NeuroSense Therapeutics
NRSN
8 hedge funds and large institutions have $112K invested in NeuroSense Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
60% more funds holding
Funds holding: 5 → 8 (+3)
4.68% less ownership
Funds ownership: 5.72% → 1.05% (-4.7%)
80% less capital invested
Capital invested by funds: $554K → $112K (-$442K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$9.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.95K |
| 3 |
Morgan Stanley
New York
|
+$1.99K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$470K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.78K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $74.6K | – | – | – |
|
|
SRL
2
Scientech Research LLC
Jersey City,
New Jersey
| $10.1K | +$8.37K | +12,584 | New |
|
|
HF
3
HRT Financial
New York
| $10K | +$9.3K | +13,998 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $9.39K | +$7.95K | +11,963 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $4.31K | -$2.77K | -4,169 | -43% |
|
|
6
Morgan Stanley
New York
| $2.36K | +$1.99K | +3,000 | New |
|
7
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| $42 | +$36 | +54 | New |
|
|
AC
9
Armistice Capital
New York
| – | -$470K | -662,000 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$8.78K | -11,702 | Closed |
|
NRSN Hedge Fund Activity: Q4 2023 in Review
8 of the 6,861 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2023, worth a combined $112K — down 80% from $554K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NRSN positions and 2 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $9.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $470K sold.
- 8 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2023, up from 5 in Q3 2023.
- Funds reported $112K of NeuroSense Therapeutics stock for Q4 2023, down 80% quarter-over-quarter.
- 5 funds opened new NeuroSense Therapeutics positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest NeuroSense Therapeutics buyer in Q4 2023 was HRT Financial, an estimated $9.3K added.
- The largest NeuroSense Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $470K sold.
Based on aggregated 13F filings for Q4 2023.